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Sir,
Unprecedented advances have occurred in the treatment of
chronic hepatitis B during the past 5 years. However, the
introduction of orally active antiviral nucleoside/nucleotide analogue treatments has seen the emergence of drug resistance as the
major factor limiting their efficacy.
The first of these agents to be used clinically was lamivudine,
which effectively suppresses viral replication, reduces disease
activity and improves liver histology.1 However, prolonged treatment with lamivudine results in the emergence of drug-resistant
hepatitis B virus (HBV) in 24% of patients after 1 year of therapy
and 70% of patients following 4 years of therapy.1 Viral resistance to lamivudine has been mapped to specific mutations in the
tyrosine–methionine–aspartate–aspartate (YMDD) motif in the
C domain of HBV polymerase, with compensatory mutations
in the B domain at V173L and L180M.1
Adefovir dipivoxil, an orally available prodrug of
adefovir monophosphate, has potent antiviral activity against
lamivudine-resistant strains of HBV.2 In contrast to lamivudine,
the cumulative incidence of adefovir resistance is 0% at 48
weeks, 3% at year 2, 6% at year 3 and 15% at year 4, due to
development of point mutations rtA181V/T or N236T in the B or
D domains, respectively.3 The adefovir-associated mutation
rtN236T in the HBV polymerase gene has been shown to maintain susceptibility to lamivudine in vivo.2 However, the other
adefovir-associated mutation, rtA181V/T, confers partial resistance to lamivudine.3 Therefore, antiviral agents active against
both adefovir- and lamivudine-resistant HBV strains are required.
In this report, molecular evidence of the emergence of adefovir resistance during antiviral therapy in two patients with
e antigen-positive chronic HBV is presented. To our knowledge,
these are the first cases reported in the Republic of Ireland of
HBV polymerase gene mutations associated with resistance to
adefovir.
Case 1 was a 36-year-old male of Asian ethnic origin who was
found to have hepatitis B e antigen (HBeAg)-positive chronic
HBV infection during a pre-employment check-up in 2003. He
was referred to St James’ Hospital, Dublin, where investigations
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Figure 1. Virological course before and after the emergence of adefovir resistance in Case 1 (a) and Case 2 (b). HBV polymerase gene mutations are shown above each
graph. Antiviral therapy is indicated below each graph.
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switched to adefovir monotherapy because of emergence of the
lamivudine resistance mutation YIDD, surprisingly developed
resistance to adefovir within 7 months of starting uninterrupted
treatment. The rapid development of this mutation suggests that
prior lamivudine treatment may predispose patients to the emergence of adefovir resistance.
In conclusion, surveillance for antiviral resistance is advised
for HBeAg-positive chronic HBV cases with incomplete viral
suppression while on adefovir treatment, particularly if the
patient has received prior treatment with lamivudine.
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Sir,
Pseudomonas aeruginosa is a significant cause of urinary tract
infections in patients with urinary catheters. Latex is the biomaterial most commonly used to make urinary catheters. We have
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revealed a raised alanine aminotransferase (ALT) level (56 IU/
mL; normal <35 IU/mL). The HBV DNA level was 6.5 log10 IU/
mL when measured using real-time PCR (HBV PCR Kit, Artus,
Hamburg, Germany). A liver biopsy performed in July 2003
revealed HBV-induced chronic hepatitis with progression to an
established cirrhosis. Treatment with adefovir (10 mg/day) was
started in August 2003. There was a significant decrease
(>1 log10 value) in the HBV DNA level following commencement of treatment (Figure 1a). However, there was evidence of
persistent HBV replication over the following 24 months during
adefovir treatment, with HBV DNA levels between 4.0 log10 and
5.0 log10 IU/mL (Figure 1a). Furthermore, ALT values remained
elevated (data not shown), suggesting persistent disease activity.
Therefore, drug resistance was suspected. Sequencing of the
HBV polymerase gene from sequential serum specimens
collected during antiviral therapy was performed, as described
previously.4 This showed that mutation rtA181V was first
detected after 30 months of adefovir treatment. No other mutations associated with resistance to other antivirals were detected
(data not shown). The patient has now started treatment with
entecavir.
Case 2 was a 35-year-old Chinese man who emigrated from
Australia to Ireland in November 2004. Hepatitis B serology
tested in Australia was consistent with HBeAg-positive chronic
HBV infection. Furthermore, liver biopsy and biochemistry tests
performed in Australia showed active hepatocellular injury.
He was started on treatment with lamivudine (100 mg/day) in
September 2003 but developed resistance in October 2004.
He was then switched to monotherapy with adefovir (10 mg/day).
No data on HBV DNA levels reported in Australia were available. In April 2005 he attended the Hepatology Clinic in St James’
Hospital, Dublin. At that time his HBV DNA level was 4.52 log10
IU/mL (Figure 1b). There was no biochemical evidence of active
hepatitis (ALT 31 IU/mL). In November 2005, biochemical findings were normal, but the HBV DNA level (3.95 log10 IU/mL)
did not show a significant decrease (<1 log10 value), and therefore resistance to adefovir was suspected. Sequencing of HBV
polymerase genes in sera collected in April and November 2005
was performed, as described previously.4 The lamivudine resistance mutation rtM180I was identified in HBV from serum collected in April 2005, but no mutation associated with adefovir
resistance was detected (Figure 1b). However, after 7 months of
uninterrupted adefovir monotherapy, sequence analysis showed
development of the adefovir-associated mutation rtA181T and
disappearance of the lamivudine resistance mutation rtM180I
(Figure 1b). Treatment using entecavir is now being considered.
Incomplete HBV suppression can contribute to the emergence
of adefovir-resistant mutations during antiviral therapy. It has
already been shown that a suboptimal virological response to
lamivudine among nucleoside-naive chronic hepatitis B patients,
defined as >3 log10 IU/mL HBV DNA after 6 months of antiviral
therapy, was associated with development of lamivudine-resistant
mutations in 63% of patients.5 In Case 1, who had no prior
treatment with lamivudine, there was persistent HBV DNAaemia,
with levels >3 log10 IU/mL for more than 2 years, before detection of the adefovir-resistant mutation, rtA181V. Therefore,
monitoring for resistance to adefovir needs to be considered in
patients with incomplete viral suppression.
Adefovir resistance is understood to occur later in the course
of treatment than lamivudine.3,5 However, in this study, one
patient (Case 2), who had prior lamivudine treatment and was

